Skip to main content

Table 1 Currently proven treatment options for mCRPC patients in the post-docetaxel space [9, 10]

From: Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space

Drug (trial)

Class (comparator)

Primary outcomes vs comparator (hazard ratio [HR])

95% CIs

P value

Abiraterone acetate + prednisone (COU-AA-301)

Antiandrogen

(prednisone/placebo)

Median OS = 14.8 vs 10.9 mo

(HR = 0.65)

0.54-0.77

< 0.0001

  

Median TTPP = 10.2 vs 6.6 mo

(HR = 0.58)

0.46-0.73

< 0.0001

  

Median rPFS = 5.6 vs 3.6 mo

(HR = 0.67)

0.58-0.78

< 0.0001

  

PSA response: 38% vs 10%

-

< 0.0001

Cabazitaxel + prednisone (TROPIC)

Chemotherapy (mitoxantrone/pred-nisone)

Median OS = 15.1 vs 12.7 mo

(HR = 0.70)

0.59-0.83

< 0.0001

  

Median PFS = 2.8 vs 1.4 mo

(HR = 0.74)

0.64-0.86

< 0.0001

  

Tumor response = 14.4% vs 4.4%

-

0.0005

  

PSA response = 39.2% vs 17.8%

-

0.0002

  1. CIs: confidence intervals; mCRPC: metastatic castrate-resistant prostate cancer; mo: months; OS: overall survival; PFS: progression-free survival; PSA: prostate-specific antigen; rPFS: radiologic PFS; TTPP: time to pain progression.